ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bluebird Bio Buys Gene-Editing Firm

by Ann M. Thayer
July 7, 2014 | APPEARED IN VOLUME 92, ISSUE 27

Bluebird Bio, a gene therapy company based in Cambridge, Mass., has acquired Precision Genome Engineering (Pregenen). Bluebird paid about $16 million in stock and assumed about $5 million in debt to buy the Seattle-based firm. It could pay up to another $135 million if therapies identified through Pregenen’s technology meet development milestones. Pregenen uses DNA-cleaving homing endonucleases and related enzymes for gene editing and targeted modification of cells for therapeutic purposes. Bluebird focuses on severe genetic and orphan diseases; it has two clinical-stage programs under way.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment